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The landmark findings of Haissaguerre *et al* have brought the catheter ablation of atrial fibrillation (AF) into an era of targeting the pulmonary veins (PVs).[1](#joa312260-bib-0001){ref-type="ref"} To date, the consensus document has consolidated the PV isolation as the cornerstone of the AF ablation. Although agreement has been reached that circumferential PV ablation to the endpoint of electric isolation is of great importance for the maintainance of sinus rhythm after ablation, the ablation strategy of solely targeting the PVs has touched the \"ceiling\" of success rate in the passing 5 years. Owing to the unsatisfying outcome for the sinus rhythm maintenance, the AF ablation has evolved into a \"PVs + x\" strategy, in which the \"x\" stands for either \"non‐PV triggering foci ablation,\" \"rotor ablation\" or \"personalized substrate ablation.\"

The varied strategies beyond the circumferential PV isolation (CPVI) suggest the fact that the mechanism of AF is far from clear. How AF is initiated and maintained remains to be elucidated. The current CPVI strategy was developed based on the observation that ectopic premature beats from the PVs initiating AF.

To date, beyond the CPVI, none of the \"x\" strategies has strongly proved its additional benefit for the AF ablation. This embarrassing situation may be due to the following reasons. First, the mechanism of AF is not fully understood. The theories on which the \"x\" strategy based might only touch one part of the truth for AF, consequently, the strategy itself can hardly demonstrate its benefit at the base of PV ablation. Second, the benefit of a certain kind of \"x\" approach performed to all the patients may be diluted by the different subgroups. That is to say, in a special subgroup of patients, a leading mechanism may play a more important role than the others. As a result, it may be more reasonable to apply an electrophysiologically based approach to a certain subgroup of patients.

In this direction, one step has just been attempted in the study performed by Masamichi *et al* [2](#joa312260-bib-0002){ref-type="ref"} In this study, the investigators hypothesized that patients had \"normal\" left atrium if the left atrial diameter was not larger than 40 mm. In this special group of patients, they analyzed the electrophysiological and clinical characteristics in the recurrent patients after CPVI. The results indicated that a high level of BNP, severe tricuspid valve regurgitation and AF/AT relapses during ablation were correlated with AF recurrence in this special subgroup of patients. This finding was interesting as it has proposed several predicting factors of recurrence that were not often referred to in other studies.[3](#joa312260-bib-0003){ref-type="ref"} Furthermore, during the second ablation, non‐PV triggers (originated from the superior vena cava, crista terminalis, ostium of the coronary sinus, and the right atrial septum) were identified as therapeutic targets in 46.2% patients, which was dramatically higher than what was previously reported.[4](#joa312260-bib-0004){ref-type="ref"} In fact, it can be postulated that either the identified predicting factors of recurrence or the electrophysiological findings in the repeat ablation may point to the role of the right atrial remodeling in the initiation and maintenance of AF, with the former as the clinical prepositions and the latter as the electrophysiological consequences. Hiram *et al* proved that right heart disease produces a substrate for AF maintenance due to RA re‐entrant activity, with an underlying substrate prominently involving RA fibrosis and conduction abnormalities.[5](#joa312260-bib-0005){ref-type="ref"} The study by Masamichi *et al* provided some clinical clues of a subgroup with \"right AF\" which warrants a special ablation strategy.

However, it still lacks convincing proof. To address this issue, several works remain to be done. First, the investigators should better explore whether there is a different substrate (especially right atrial substrate) between those patients with and without \"normal\" left atria. Second, it may be of special significance to investigate the genetic characteristics of those AF patients with the background of \"normal\" left atrium. Last, not the least, it is important to develop the tailored strategy targeting the right atrial substrate beyond the PVs in this presumed subset of patients.

Although catheter ablation has been an established therapeutic strategy for AF for more than two decades, the recurrence of atrial arrhythmias after ablation is common. How to further improve the outcome seems to be crucially important in clinical research.
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